Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $9.95.
ALLO has been the topic of several research reports. HC Wainwright lowered their price objective on shares of Allogene Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, May 16th. Stifel Nicolaus lifted their target price on shares of Allogene Therapeutics from $4.40 to $4.60 and gave the stock a “hold” rating in a research note on Tuesday, May 14th. Piper Sandler began coverage on shares of Allogene Therapeutics in a research note on Friday, May 31st. They set an “overweight” rating and a $11.00 price objective for the company. Oppenheimer reduced their price objective on shares of Allogene Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Tuesday, May 21st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of Allogene Therapeutics in a research report on Friday, March 15th.
View Our Latest Stock Analysis on ALLO
Insider Transactions at Allogene Therapeutics
Hedge Funds Weigh In On Allogene Therapeutics
Hedge funds have recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. bought a new position in Allogene Therapeutics during the 4th quarter valued at about $27,000. Axxcess Wealth Management LLC purchased a new stake in Allogene Therapeutics during the 4th quarter valued at approximately $34,000. Aaron Wealth Advisors LLC purchased a new stake in Allogene Therapeutics during the 4th quarter valued at approximately $34,000. EP Wealth Advisors LLC purchased a new position in shares of Allogene Therapeutics in the third quarter valued at $34,000. Finally, Victory Capital Management Inc. grew its holdings in shares of Allogene Therapeutics by 23.1% in the fourth quarter. Victory Capital Management Inc. now owns 14,283 shares of the company’s stock valued at $46,000 after purchasing an additional 2,680 shares in the last quarter. Institutional investors own 83.63% of the company’s stock.
Allogene Therapeutics Stock Down 7.3 %
Allogene Therapeutics stock opened at $2.16 on Wednesday. Allogene Therapeutics has a 12-month low of $2.13 and a 12-month high of $6.05. The firm’s fifty day moving average is $2.61 and its 200 day moving average is $3.49. The company has a market capitalization of $451.44 million, a PE ratio of -1.21 and a beta of 0.86.
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.81%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.01 million. During the same quarter in the prior year, the company posted ($0.68) earnings per share. The business’s revenue was down 26.7% on a year-over-year basis. Sell-side analysts expect that Allogene Therapeutics will post -1.5 EPS for the current fiscal year.
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Recommended Stories
- Five stocks we like better than Allogene Therapeutics
- The How And Why of Investing in Oil Stocks
- RXO Shares Surge Following New Acquisition Deal
- What is a Secondary Public Offering? What Investors Need to Know
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- EV Stocks and How to Profit from Them
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.